Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Source: View publication →
The RELATIVITY-047 trial demonstrated that combined blockade of LAG-3 and PD-1 with a fixed-dose combination of relatlimab and nivolumab significantly prolonged progression-free survival compared to nivolumab alone in patients with previously untreated advanced melanoma.
Key Findings
Study Design
Study Limitations
Clinical Significance
The RELATIVITY-047 trial established LAG-3 as the third clinically validated immune checkpoint pathway in oncology. The relatlimab-nivolumab fixed-dose combination (subsequently approved as Opdualag) provides a highly efficacious front-line treatment option that offers superior progression-free survival compared to anti-PD-1 monotherapy, while avoiding the severely high toxicity rates historically seen with anti-CTLA-4 (ipilimumab) and anti-PD-1 combinations.
Historical Context
Prior to this trial, first-line immunotherapy for advanced melanoma was dominated by PD-1 inhibitors (nivolumab or pembrolizumab) alone or in combination with the CTLA-4 inhibitor ipilimumab. While the nivolumab-ipilimumab combination improved survival, it was associated with high rates of severe toxicity (over 50% grade 3/4 events). Lymphocyte-activation gene 3 (LAG-3) was identified as another key inhibitory immune checkpoint receptor contributing to T-cell exhaustion. RELATIVITY-047 was the first pivotal phase 3 trial to demonstrate that targeting LAG-3 in tandem with PD-1 improves clinical outcomes, leading to the regulatory approval of the first LAG-3 blocking antibody.
Guided Discussion
High-yield insights from every perspective
How does the mechanism of action of relatlimab, a LAG-3 inhibitor, differ from and complement that of nivolumab, a PD-1 inhibitor, in reversing T-cell exhaustion in melanoma?
Key Response
LAG-3 and PD-1 are distinct inhibitory immune checkpoints that are often co-expressed on exhausted T cells in the tumor microenvironment. While PD-1 signaling primarily inhibits early T-cell receptor signaling by recruiting SHP-2, LAG-3 binds to MHC class II on antigen-presenting cells to suppress T-cell activation and proliferation. Dual blockade acts synergistically to restore T-cell effector function and enhance anti-tumor immunity better than either pathway alone.
Considering the RELATIVITY-047 trial results, how does the adverse event profile of relatlimab-nivolumab compare to historical data for ipilimumab-nivolumab, and how does this influence your first-line treatment choice for a patient with advanced melanoma?
Key Response
The incidence of grade 3 or 4 treatment-related adverse events with relatlimab-nivolumab is approximately 18.9 percent, which is significantly lower than the historical rate of roughly 55 percent seen with ipilimumab-nivolumab. This favorable toxicity profile makes relatlimab-nivolumab a highly attractive first-line option, especially for patients who require combination therapy but might not tolerate the severe immune-related adverse events associated with anti-CTLA-4 therapy.
In the RELATIVITY-047 trial, what was the impact of LAG-3 expression levels on progression-free survival, and does this data support using LAG-3 expression as a predictive biomarker to exclude patients from dual therapy?
Key Response
While patients with LAG-3 expression of 1 percent or greater showed a robust clinical benefit, subgroup analyses indicated that patients with less than 1 percent expression also derived a progression-free survival benefit from the combination compared to nivolumab alone, albeit the magnitude was smaller. Therefore, LAG-3 expression is not currently utilized as a strict exclusionary biomarker for patient selection in clinical practice.
With relatlimab-nivolumab established as a first-line standard of care, how should we conceptualize the optimal sequencing of immunotherapy, particularly regarding the efficacy of salvage ipilimumab after progression on dual PD-1/LAG-3 blockade?
Key Response
The trial establishes a highly active and tolerable upfront option but complicates sequencing. It remains an open clinical question whether patients progressing on PD-1/LAG-3 blockade will respond to subsequent CTLA-4 inhibition (ipilimumab) as robustly as they might after PD-1 monotherapy. Attendings must weigh the upfront efficacy of relatlimab-nivolumab against the lack of mature data on effective second-line immunotherapy salvage strategies.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The RELATIVITY-047 trial utilized a fixed-dose combination of relatlimab and nivolumab. What are the pharmacological and trial design trade-offs of using a fixed-dose combination versus separate infusions in a phase 3 pivotal trial for a novel checkpoint inhibitor?
Key Response
A fixed-dose combination simplifies administration, reduces pharmacy preparation time, and ensures strict compliance with the dual therapy regimen. However, from a research and pharmacological standpoint, it prevents dose titration of individual components, complicates the attribution of specific adverse events or pharmacokinetic interactions to a single agent, and restricts the ability to decouple the drugs if dose-limiting toxicities occur.
A critical reviewer might argue that the ideal comparator arm for RELATIVITY-047 should have been ipilimumab plus nivolumab rather than nivolumab alone. How does the choice of nivolumab monotherapy as the control affect the trial's clinical utility and editorial significance?
Key Response
While nivolumab monotherapy is a widely accepted standard of care and a valid control, the lack of a head-to-head comparison with ipilimumab-nivolumab leaves a major clinical question unanswered. It is unclear if relatlimab-nivolumab offers superior or non-inferior efficacy to the most potent existing dual-immunotherapy regimen, or merely better tolerability. The absence of this arm limits the ability to definitively rank it above ipilimumab-nivolumab in the treatment hierarchy.
Based on the progression-free survival benefit and safety profile demonstrated in RELATIVITY-047, how should current clinical practice guidelines update their algorithms for the first-line treatment of advanced melanoma, and how should they stratify patients between anti-PD-1 monotherapy, nivolumab-relatlimab, and nivolumab-ipilimumab?
Key Response
Guidelines such as NCCN and ESMO have incorporated nivolumab-relatlimab as a preferred Category 1 first-line option. The committee must integrate the Level 1 evidence of superior progression-free survival over PD-1 monotherapy and better safety than historical CTLA-4 combinations. Recommendations should emphasize shared decision-making, positioning nivolumab-relatlimab as a primary choice for patients needing combination therapy while reserving ipilimumab-based regimens for high-risk scenarios like asymptomatic brain metastases where robust specific data already exists.
Clinical Landscape
Noteworthy Related Trials
CheckMate 067 Trial
Tested
Nivolumab plus Ipilimumab or Nivolumab alone
Population
Previously untreated advanced melanoma
Comparator
Ipilimumab alone
Endpoint
Progression-free survival and overall survival
KEYNOTE-006 Trial
Tested
Pembrolizumab
Population
Patients with advanced melanoma
Comparator
Ipilimumab
Endpoint
Progression-free survival and overall survival
CheckMate 066 Trial
Tested
Nivolumab
Population
Previously untreated advanced melanoma without a BRAF mutation
Comparator
Dacarbazine
Endpoint
Overall survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis